Skip to main content

Table 5 Comparison of demographic and clinical characteristics of participants recruited pre-legalization with and without cannabis urine screen data

From: Cannabis use in patients treated for opioid use disorder pre- and post-recreational cannabis legalization in Canada

Characteristic Total pre-legalization sample
(n = 602)
Pre-legalization sample with cannabis urine drug screens followed through post-legalization period
(n = 199)
Age in years; mean (SD) 38.9 (10.4) 40.6 (11.1)
Male sex; n (%) 343 (57) 97 (48.7)
Type of MAT; n (%)
  → Methadone 498 (82.9) 171 (85.9)
  → Buprenorphine 103 (17.1) 28 (14.1)
Dose (mg/day); median (IQR)
  → Methadone 65 (61) 75 (63)
  → Buprenorphine 12 (8) 12 (7)
Length of time in treatment (years); median (IQR) 2 (4.9) 3 (5)
Opioid abstinencea; n (%) 176 (29.2) 66 (33.2)
Percentage of opioid-positive urine drug screens amongst non-abstainersa; mean (SD) 21.1 (23.3) 16.5 (18.7)
Self-reported cannabis use; n (%) 330 (54.8%) 111 (55.8)
Days of use in the last 30 days amongst users; median (IQR) 30 (16) 30 (15)
  1. Characteristics of participants recruited pre-legalization with and without cannabis urine screen data
  2. SD standard deviation, IQR interquartile range